<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Hernia</journal-id><journal-id journal-id-type="iso-abbrev">Hernia</journal-id><journal-title-group><journal-title>Hernia</journal-title></journal-title-group><issn pub-type="ppub">1265-4906</issn><issn pub-type="epub">1248-9204</issn><publisher><publisher-name>Springer Paris</publisher-name><publisher-loc>Paris</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407928</article-id><article-id pub-id-type="pmc">PMC12102115</article-id>
<article-id pub-id-type="publisher-id">3369</article-id><article-id pub-id-type="doi">10.1007/s10029-025-03369-w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effectiveness of pre-operative chemical component separation with computed tomography-guided intramuscular injection of OnabotulinumtoxinA in outcomes of large complex incisional ventral abdominal hernia repair: a propensity score-weighted comparative analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3328-2919</contrib-id><name><surname>Jahangiri</surname><given-names>Younes</given-names></name><address><email>y.jahangiri@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Goldsmith</surname><given-names>Dylan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Banks-Venegoni</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fritz</surname><given-names>Gregory</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zambito</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jiao</surname><given-names>Albert</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>King</surname><given-names>Lane</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Castle</surname><given-names>Jordan</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Quasem</surname><given-names>Khaleel</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Morrison</surname><given-names>James</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Division of Interventional Radiology, Corewell Health West Michigan, 100 Michigan St. NE, Grand Rapids, MI 49503 USA </aff><aff id="Aff2"><label>2</label>Department of Surgery, Corewell Health West Michigan, Grand Rapids, MI USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03vek6s52</institution-id><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Department of Radiology, Brigham and Women&#x02019;s Hospital, </institution><institution>Harvard Medical School, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/024mw5h28</institution-id><institution-id institution-id-type="GRID">grid.170205.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7822</institution-id><institution>Department of Anesthesia &#x00026; Critical Care, </institution><institution>The University of Chicago, </institution></institution-wrap>Chicago, IL USA </aff><aff id="Aff5"><label>5</label>Division of Interventional Radiology, Inland Imaging, Spokane, WA USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05hs6h993</institution-id><institution-id institution-id-type="GRID">grid.17088.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2195 6501</institution-id><institution>College of Human Medicine, </institution><institution>Michigan State University, </institution></institution-wrap>Grand Rapids, MI USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05hs6h993</institution-id><institution-id institution-id-type="GRID">grid.17088.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2195 6501</institution-id><institution>Department of Radiology, </institution><institution>Michigan State University, </institution></institution-wrap>East Lansing, MI USA </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>29</volume><issue>1</issue><elocation-id>171</elocation-id><history><date date-type="received"><day>1</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>4</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">To evaluate the effectiveness of chemical component separation (CCS) via computed tomography (CT)-guided intramuscular injection of OnabotulinumtoxinA (Botox) in postoperative recurrence of large complex incisional ventral abdominal hernias.</p></sec><sec><title>Materials and methods</title><p id="Par2">A total of 97 patients with large ventral abdominal hernias who underwent complex hernia repair between November 2017 and October 2021 after (<italic>n</italic>&#x02009;=&#x02009;37) (Botox) or without (<italic>n</italic>&#x02009;=&#x02009;60) Botox injection (no-Botox) were included in the study. Data were summarized as median [min&#x02013;max] or frequency (%) and analyzed using the Fisher's exact test, Mann&#x02013;Whitney U test, multivariate logistic regression with backward stepwise selection of covariates and augmented inverse probability-weighted analysis with Stata BE 18.0 at a significance level set at 0.10.</p></sec><sec><title>Results</title><p id="Par3">There was no statistically significant difference between Botox and no-Botox groups in patients&#x02019; age (64[34&#x02013;78] vs. 62[24&#x02013;94], <italic>p</italic>&#x02009;=&#x02009;0.885), sex (females: 46% vs. 55%, <italic>p</italic>&#x02009;=&#x02009;0.410), body mass index (BMI) (32[19&#x02013;53] vs. 31[18&#x02013;50], <italic>p</italic>&#x02009;=&#x02009;0.431) and hernia volume (3197[226&#x02013;24232] vs. 2366[140&#x02013;24314], <italic>p</italic>&#x02009;=&#x02009;0.458). Median follow-up duration was 38[2&#x02013;72] months in Botox and 48[6&#x02013;81] months in no-Botox groups (<italic>p</italic>&#x02009;=&#x02009;0.010), and all-time hernia recurrence was 8% in Botox and 22% in no-Botox groups, respectively (<italic>p</italic>&#x02009;=&#x02009;0.097). In multivariate regression analysis, CCS, hernia volume, implanted mesh type and overall postoperative complications were associated with hernia recurrence. After propensity score weighting for follow-up duration, surgical component separation and postoperative discharge destination, CCS was associated with 71% reduced risk of hernia recurrence (<italic>p</italic>&#x02009;=&#x02009;0.045).</p></sec><sec><title>Conclusion</title><p id="Par4">The results of this study suggests that CT-guided chemical component separation with intramuscular injection of OnabotulinumtoxinA may be effective in reducing the risk of post-surgical recurrence of large complex incisional ventral abdominal hernias.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Complex hernia</kwd><kwd>Ventral hernia</kwd><kwd>Component separation</kwd><kwd>Botox</kwd><kwd>OnabotulinumtoxinA</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag France SAS, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Large ventral hernias are defined as abdominal wall hernias with diameter &#x02265;&#x02009;10 cm by the European Hernia Society [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Recurrence is an important complication in the surgical repair of large, complex ventral hernias. The rate of incisional and ventral hernia repairs that recurred and required reoperation was substantial: up to 16.0% for the open surgical approach and 18.8% for the minimally invasive approach [<xref ref-type="bibr" rid="CR3">3</xref>]. Factors that are predictive of hernia recurrence include smoking, diabetes, chronic obstructive pulmonary disease (COPD), ASA grade III&#x02013;IV, steroid use, and the repair of incisional or recurrent hernias as opposed to primary hernias [<xref ref-type="bibr" rid="CR4">4</xref>]. Intraoperative factors impacting recurrence rates include achieving fascial closure over bridged repair, using ventral mesh over sutures only, opting for synthetic over biologic mesh, and choosing laparoscopic over open repair [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par6">Current management of this condition shows a wide variety of approaches. Despite most surgeons adhering to the Ventral Hernia Working Group's recommendations on preoperative optimization and lifestyle changes, such as smoking cessation more than four weeks before surgery, maintaining HbA1c below 7% in diabetic patients, and weight-loss regimens to achieve a BMI below 30 kg/m<sup>2</sup>, many surgeons were not deterred from operating if patients did not meet these targets [<xref ref-type="bibr" rid="CR5">5</xref>]. Surgeons have adopted several practices to aid in achieving primary closure and reduce the risk of complex ventral hernia recurrence, including, surgical mesh placement, aponeuroplasty, pneumoperitoneum, tissue expanders, and surgical component separation &#x02013; a release of the abdominal musculature to increase laxity [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par7">Use of chemical component separations (CCS) with OnabotulinumtoxinA is a relatively recent advancement in the management of complex large ventral hernias, aiding the surgeon in achieving primary closure [<xref ref-type="bibr" rid="CR7">7</xref>]. OnabotulinumtoxinA is a potent neurolytic toxin extracted from Clostridium botulinum, and is famous for well-known food-borne intoxication [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. This drug exerts its effect by induction of temporary flaccid paralysis of the abdominal wall musculature by presynaptic acetylcholine blockade, reaching its maximal effect by two weeks [<xref ref-type="bibr" rid="CR10">10</xref>]. This surgical adjunct has been demonstrated to be safe and effective in creating abdominal wall laxity to decrease hernia width and assist in primary closure [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. However, the current evidence directly associating this preoperative treatment with lower recurrence rates is sparse. The purpose of this study is to assess the efficacy of chemical component separation with OnabotulinumtoxinA in reducing the risk of recurrence of complex large ventral abdominal hernias after surgical repair.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Patients</title><p id="Par8">This single-institution retrospective case control study&#x0200b; was evaluated by the local Institutional Review Board (IRB) and a consent waiver was granted. The Local Electronic Medical Record system was queried using the CPT codes associated with incisional hernia repair (49560, 49561, 49565, 49566, 49585 and 49587). A total of 468 patients were identified who had incisional hernia repair between November 2017 and October 2021. All patients &#x02265;&#x02009;18 years of age who had undergone surgical repair for large or complex ventral hernias were included in the initial evaluation (<italic>n</italic>&#x02009;= 148). After exclusion of cases without preoperative imaging, those with fascial defects measuring less than 10 cm or traumatic etiology of the ventral hernia (<italic>n</italic>&#x02009;= 51), 97 subjects were enrolled in the study. Among the enrolled subjects, 37 patients underwent preoperative CT-guided abdominal wall CCS with OnabotulinumtoxinA (Botox group) and 60 were those who had not received CCS (no Botox group) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Patients presenting with fascial defects greater than 8&#x000a0;cm were considered candidates for chemical component separation using Botox injection. The decision to proceed with Botox injection was based on hernia size, a shared decision-making discussion between the surgeon and the patient, and the patient&#x02019;s preference. Data regarding patients&#x02019; demographics, clinical status, clinical and imaging hernia characteristics, surgical technique, and postoperative follow-up were collected.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow Chart demonstrating study patient selection</p></caption><graphic xlink:href="10029_2025_3369_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec4"><title>Botox injection technique</title><p id="Par9">A computed tomography (CT)-guided percutaneous bilateral injection of Botox into the abdominal wall musculature was performed for each patient in the Botox group using the technique described by Zielinski and Zendehas [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Briefly, 300 international units of OnabotulinumtoxinA were diluted in 180 ml of sterile normal saline. Six total sites were selected&#x02014;three on each side along the mid-axillary line: one immediately below the rib cage, one immediately above the iliac crest, and a third midpoint site equidistant between them. The sites were prepped using maximal sterile technique. Moderate sedation was provided with 1&#x02013;2 mg midazolam and 50 &#x003bc;gr fentanyl with continuous monitoring. Local anesthesia was applied at each site. Under CT fluoroscopic guidance, a 22-guage needle was advanced into each of the external oblique, internal oblique, and transverse abdominis muscles at each site (superior, mid, and inferior bilaterally) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). After confirming negative test aspiration, 10 mL of diluted Botox serotype A was injected into each muscle at each site for a total of 18 injections. Post-injection imaging demonstrated fluid expansion within the muscle layers, confirming appropriate intramuscular delivery.<fig id="Fig2"><label>Fig. 2</label><caption><p>Computed tomography (CT)-guided injection of OnabotulinumtoxinA into the abdominal wall muscles, with three injection points (upper, mid, and lower) per muscle, totaling nine injections per side. The injections on the right side are shown here</p></caption><graphic xlink:href="10029_2025_3369_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec5"><title>Surgical repair technique</title><p id="Par10">Under general anesthesia and sterile technique, a midline incision was created and the previous scar tissue was excised. The subcutaneous tissues were divided down to the fascia. Adhesions were lysed sharply and/or bluntly as needed to free any bowel or omentum from the abdominal wall and hernia sac. Any nonviable tissue was excised, and the hernia sacs were resected circumferentially to expose intact fascial edges. The specific surgical technique varied based on defect size, location, and surgeon preference. In cases where primary fascial closure was feasible without undue tension, a standard retrorectus (Rives-Stoppa) repair was performed. In cases with larger defects requiring additional myofascial advancement, posterior component separation via transversus abdominis release (TAR) was performed. External oblique release (anterior component separation) was used selectively when additional mobilization was required. Depending on the defect size and location, a suitable prosthetic or biologic mesh was selected and positioned in either the retrorectus (sublay) or underlay plane. Mesh fixation was achieved with a combination of transfascial sutures or running sutures, ensuring wide overlap of the defect. Posterior and anterior fascial layers were then closed, typically with running or interrupted absorbable (e.g., polydiaxanone (PDS)) sutures.</p><p id="Par11">Incisional negative-pressure wound therapy was applied postoperatively per surgeon preference.</p></sec><sec id="Sec6"><title>Definition of terms</title><p id="Par12">Hernia and abdominal cavity dimensions were measured on the pre-surgical imaging (CT or MRI) according to the method suggested by Tanaka et al. [<xref ref-type="bibr" rid="CR15">15</xref>] (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Hernia and abdominal cavity volumes were calculated using the formula for ellipsoid shapes, also suggested by the same group: <inline-formula id="IEq1"><alternatives><tex-math id="d33e386">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Volume=\frac{4}{3}\times \pi \times (length \times width\times height)$$\end{document}</tex-math><mml:math id="d33e391"><mml:mrow><mml:mi>V</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mn>4</mml:mn><mml:mn>3</mml:mn></mml:mfrac><mml:mo>&#x000d7;</mml:mo><mml:mi>&#x003c0;</mml:mi><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mo>&#x000d7;</mml:mo><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mi>d</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mo>&#x000d7;</mml:mo><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="10029_2025_3369_Article_IEq1.gif"/></alternatives></inline-formula>. All measurements were performed by a trained interventional radiology resident (DG).<fig id="Fig3"><label>Fig. 3</label><caption><p>Non-contrast-enhanced abdominal computed tomography denoting measurements of abdominal and hernia cavities dimensions in axial (a) and sagittal (b) projections. On the axial projection (<bold>a</bold>), line A denotes the widest axial diameter of the hernia sac, line B is measured at the hernia neck, and lines C and D denote the widest transverse and anteroposterior abdominal cavity dimensions, respectively. On the sagittal projection (<bold>b</bold>), line A denotes the widest craniocaudal dimension of the hernia sac, line B denotes the widest craniocaudal dimension of the hernia neck, line C denotes the widest anteroposterior dimension of the hernia sac, and line D is measuring the widest craniocaudal dimension of the abdominal cavity from the diaphragm to the superior aspect of the pubis</p></caption><graphic xlink:href="10029_2025_3369_Fig3_HTML" id="MO3"/></fig></p><p id="Par13">Hernia location was classified as midline or lateral according to the European Hernia Society (EHS) 2009 classification [<xref ref-type="bibr" rid="CR1">1</xref>]. Follow-up duration was defined based on any imaging or clinical follow-up documenting the status of treated hernia. All-time hernia recurrence was defined as documented recurrence of the repaired hernia during the entire postsurgical follow-up period. Clinical evaluation was performed during follow-up visits to assess for any signs or symptoms suggestive of hernia recurrence, such as bulging, pain, or functional impairment. Definitive hernia recurrence was objectively assessed using cross-sectional imaging (CT or MRI) to evaluate the integrity of the abdominal wall at the surgical site. Recurrence was defined as the presence of a full-thickness fascial defect with recurrent protrusion of the intra-abdominal contents, as confirmed on imaging.</p></sec><sec id="Sec7"><title>Statistics</title><p id="Par14">Categorical and numerical data were summarized as frequency (percentage) or median (min &#x02013; max), and were compared between two groups using the Fisher&#x02019;s exact test or the Mann&#x02013;Whitney U test, respectively.</p><p id="Par15">To assess multivariate-adjusted association between chemical component separation using Botox injection with hernia recurrence, a multivariate logistic regression model was applied. A stepwise technique with forward variable selection approach was used. Given the significant difference in follow-up duration between treatment arms, the natural logarithm of follow-up time was fixed in the model as the offset variable. The entry and removal significance thresholds were set at 0.1 and 0.2, respectively. Between-covariate interactions were evaluated using the Pearson&#x02019;s correlation coefficients with Bonferroni adjustment, and any statistically significant interaction terms were included in the final multivariate model.</p><p id="Par16">Next, to minimize selection bias, a propensity score-weighted approach was conducted. For this purpose, an augmented inverse propensity-weighted (AIPW) model was constructed. This method is a doubly-robust technique that has been shown to carry less bias compared to other techniques of propensity score estimation such as regression or inverse probability weighting methods [<xref ref-type="bibr" rid="CR16">16</xref>]. Potential confounders were selected based on their significant association with treatment (Botox) and outcome (hernia recurrence) as well as scientific inference. Any variable with standardized mean differences &#x02265;&#x02009;0.20, were also included in the main model for a multivariate-adjusted model. Absolute and relative average treatment effects (ATE) of chemical component separation were quantified. Study power was calculated based on differences of hernia recurrence between Botox and no Botox groups. All analyses were performed with Stata BE 18.0, and the significance level was set at 0.10.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Comparison between Botox and no Botox groups</title><p id="Par17">The median time between Botox injection and surgical repair was 30 days (range: 8&#x02013;58 days), and the median time between the pre-surgical imaging and hernia repair was 3.1 months (range: 0&#x02013;26.9). A comparison of the treatment arms is presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. There was no statistically significant difference between Botox and no Botox groups regarding patients&#x02019; demographics, pre-surgical clinical status and comorbidities. A higher number of patients in Botox group underwent surgical component separation (SCS) and also had home without need for assistance as their discharge destination compared to no Botox group (49% versus 22%, <italic>p</italic>&#x02009;= 0.007; and 92% versus 73%, <italic>p</italic>&#x02009;= 0.041, respectively). Primary fascial closure was achieved in 95% of the Botox group versus 92% of the non-Botox group (<italic>p</italic>&#x02009;= 0.705). The Botox group had a shorter total median follow-up duration (38 versus 48 months, <italic>p</italic>&#x02009;= 0.010) and lower hernia recurrence rates (8% versus 22%, <italic>p</italic>&#x02009;= 0.097). Analysis power at the significance level of 0.1 was 0.473.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Comparison between subjects in Botox and non-Botox groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="3">Pre-operative Botox injection<sup>1</sup></th></tr><tr><th align="left"/><th align="left">No</th><th align="left">Yes</th><th align="left"><italic>p</italic>-value<sup>2,3</sup></th></tr><tr><th align="left"/><th align="left"><italic>n</italic> = 60 (62%)</th><th align="left"><italic>n</italic> = 37 (38%)</th><th align="left"/></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">62 (24&#x02013;94)</td><td align="left">64 (34&#x02013;78)</td><td align="left">0.885</td></tr><tr><td align="left" colspan="4">Sex</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Female</td><td align="left">33 (55%)</td><td align="left">17 (46%)</td><td align="left">0.410</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Male</td><td align="left">27 (45%)</td><td align="left">20 (54%)</td><td align="left"/></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="left">31 (18&#x02013;50)</td><td align="left">32 (19&#x02013;53)</td><td align="left">0.431</td></tr><tr><td align="left" colspan="4">Diabetes</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">38 (63%)</td><td align="left">27 (73%)</td><td align="left">0.379</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">22 (37%)</td><td align="left">10 (27%)</td><td align="left"/></tr><tr><td align="left" colspan="4">CAD</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">56 (95%)</td><td align="left">32 (86%)</td><td align="left">0.254</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">3 (5%)</td><td align="left">5 (14%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Previous hernia repair</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">36 (62%)</td><td align="left">17 (46%)</td><td align="left">0.142</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">22 (38%)</td><td align="left">20 (54%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Previous mesh implantation</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">35 (61%)</td><td align="left">17 (55%)</td><td align="left">0.651</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">22 (39%)</td><td align="left">14 (45%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Smoking status</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Never</td><td align="left">29 (48%)</td><td align="left">16 (43%)</td><td align="left">0.679</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Current or former</td><td align="left">31 (52%)</td><td align="left">21 (57%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Recent smoking status</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Never smoked</td><td align="left">45 (75%)</td><td align="left">32 (86%)</td><td align="left">0.205</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Current smoker or quit during the past year</td><td align="left">15 (25%)</td><td align="left">5 (14%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Location of hernia</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;midline</td><td align="left">59 (98%)</td><td align="left">36 (97%)</td><td align="left">1.000</td></tr><tr><td align="left">lateral</td><td align="left">1 (2%)</td><td align="left">1 (3%)</td><td align="left"/></tr><tr><td align="left">Hernia Volume (cm<sup>3</sup>)</td><td align="left">2366 (140&#x02013;24314)</td><td align="left">3197 (226&#x02013;24,232)</td><td align="left">0.458</td></tr><tr><td align="left">Abdominal Cavity Volume (cm<sup>3</sup>)</td><td align="left">50966 (19698&#x02013;113636)</td><td align="left">39157 (18982&#x02013;112922)</td><td align="left">0.238</td></tr><tr><td align="left">Hernia-to-abdominal Cavity Ratio (%)</td><td align="left">5 (0&#x02013;48)</td><td align="left">6 (0&#x02013;99)</td><td align="left">0.375</td></tr><tr><td align="left" colspan="4">Complication associated with Botox injection</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">na</td><td align="left">37 (100%)</td><td align="left">na</td></tr><tr><td align="left">Botox-to-surgery time (days)</td><td align="left">na</td><td align="left">30 (8&#x02013;58)</td><td align="left">na</td></tr><tr><td align="left" colspan="4">Retrorectus surgical technique</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">15 (25%)</td><td align="left">7 (19%)</td><td align="left">0.620</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">45 (75%)</td><td align="left">30 (81%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Primary fascial closure</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">5 (8%)</td><td align="left">2 (5%)</td><td align="left">0.705</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">55 (92%)</td><td align="left">35 (95%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Delayed closure</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">53 (88%)</td><td align="left">36 (97%)</td><td align="left">0.150</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">7 (12%)</td><td align="left">1 (3%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Surgical component separation</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left"><bold>47 (78%)</bold></td><td align="left"><bold>19 (51%)</bold></td><td align="left"><bold>0.007</bold></td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left"><bold>13 (22%)</bold></td><td align="left"><bold>18 (49%)</bold></td><td align="left"/></tr><tr><td align="left" colspan="4">Application of mesh</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">5 (8%)</td><td align="left">3 (8%)</td><td align="left">1.000</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">55 (92%)</td><td align="left">34 (92%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Mesh type</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;None</td><td align="left">5 (8%)</td><td align="left">3 (8%)</td><td align="left">0.593</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Polypropylene (Prolene)</td><td align="left">24 (40%)</td><td align="left">21 (57%)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Synthetic Biodegradable (Vicryl, Phasix)</td><td align="left">9 (15%)</td><td align="left">3 (8%)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Composite Mesh (Bard Ventralex)</td><td align="left">14 (23%)</td><td align="left">7 (19%)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Biologic (Strattice)</td><td align="left">8 (13%)</td><td align="left">3 (8%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Additional intraoperative procedures other than hernia repair</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">44 (73%)</td><td align="left">30 (81%)</td><td align="left">0.466</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">16 (27%)</td><td align="left">7 (19%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Need for blood transfusion during surgery</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">57 (97%)</td><td align="left">37 (100%)</td><td align="left">0.521</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">2 (3%)</td><td align="left">0 (0%)</td><td align="left"/></tr><tr><td align="left">Estimated Blood Loss (ml)</td><td align="left">75 (15&#x02013;1000)</td><td align="left">100 (10&#x02013;300)</td><td align="left">0.434</td></tr><tr><td align="left">Hospital stay (days)</td><td align="left">3 (0&#x02013;20)</td><td align="left">4 (1&#x02013;20)</td><td align="left">0.688</td></tr><tr><td align="left" colspan="4">Discharge destination</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Home</td><td align="left"><bold>44 (73%)</bold></td><td align="left"><bold>34 (92%)</bold></td><td align="left"><bold>0.041</bold></td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Home w/Assistance</td><td align="left"><bold>12 (20%)</bold></td><td align="left"><bold>1 (3%)</bold></td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Subacute Rehab</td><td align="left"><bold>3 (5%)</bold></td><td align="left"><bold>1 (3%)</bold></td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Inpatient rehab</td><td align="left"><bold>1 (2%)</bold></td><td align="left"><bold>1 (3%)</bold></td><td align="left"/></tr><tr><td align="left" colspan="4">Any complications</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">41 (69%)</td><td align="left">24 (67%)</td><td align="left">0.822</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">18 (31%)</td><td align="left">12 (33%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Post-operative pain control issues</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">57 (95%)</td><td align="left">36 (97%)</td><td align="left">1.000</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">3 (5%)</td><td align="left">1 (3%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Reoperation for hernia repair during hospitalization</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">60 (100%)</td><td align="left">37 (100%)</td><td align="left">na</td></tr><tr><td align="left" colspan="4">30-day hernia reoperation</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">60 (100%)</td><td align="left">37 (100%)</td><td align="left">na</td></tr><tr><td align="left" colspan="4">Hernia recurrence during entire postop follow-up</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left"><bold>47 (78%)</bold></td><td align="left"><bold>34 (92%)</bold></td><td align="left"><bold>0.097</bold></td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left"><bold>13 (22%)</bold></td><td align="left"><bold>3 (8%)</bold></td><td align="left"/></tr><tr><td align="left" colspan="4">Alive at last follow-up?</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">60 (100%)</td><td align="left">37 (100%)</td><td align="left">na</td></tr><tr><td align="left">Follow-up duration (months)</td><td align="left"><bold>48 (6&#x02013;81)</bold></td><td align="left"><bold>38 (2&#x02013;72)</bold></td><td align="left"><bold>0.010</bold></td></tr></tbody></table><table-wrap-foot><p>1. Data summarized as frequency (%) for categorical variables and median (min &#x02013; max) for numerical values</p><p>2. Percentages are compared using the Fisher's exact test, and the median values are compared with the Mann&#x02013;Whitney U test</p><p>3. Statistically significant differences are shown in bold. Statistical significance level is set at 0.10</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Subpopulation comparison (Botox-only versus surgical component separation only)</title><p id="Par18">There was no statistically significant difference in primary fascial closure rates neither between SCS and no SCS groups (94% versus 91%, <italic>p</italic>&#x02009;= 1.000) nor when Botox-only group was compared with the SCS-only group (91% versus 92%, <italic>p</italic>&#x02009;= 1.000). One out of 19 (5%) patients with Botox only treatment and 3/13 (23%) patients with surgical component separation only treatment had hernia recurrence on follow-up (<italic>p</italic>&#x02009;= 0.279) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Analysis power for this comparison was 0.200 at significance level of 0.1.<fig id="Fig4"><label>Fig. 4</label><caption><p>Comparisons of ventral hernia recurrence rates after surgical repair of large incisional ventral abdominal hernias.&#x000a0;Both non-weighted and propensity score-weighted comparisons are presented.&#x000a0;The figure highlights non-weighted comparisons for all subjects as well as a subgroup of patients treated with surgical component separation only, versus those treated with Botox (chemical component separation) without surgical component separation. Differences were assessed using the Fisher&#x02019;s exact test, and <italic>p</italic> values are provided</p></caption><graphic xlink:href="10029_2025_3369_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec11"><title>Factors associated with hernia recurrence</title><p id="Par19">Patients with hernia recurrence during follow-up (16/97 (16%)) had larger median hernia volumes (4221 versus 2316 cm<sup>3</sup>, <italic>p</italic>&#x02009;= 0.077), higher rate of biologic mesh implantation (31% versus 7%, <italic>p</italic>&#x02009;= 0.020), longer median hospital stay (7 versus 3&#x000a0;days, p&#x02009;= 0.002), higher rate of home with assist as discharge destination (31% versus 10%, <italic>p</italic>&#x02009;= 0.088), and higher rates of postoperative complications (94% versus 19%, <italic>p</italic>&#x02009;&#x0003c; 0.001) including postoperative pain control issues (19% versus 1%, <italic>p</italic>&#x02009;= 0.014) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Comparison between subjects with and without all-time hernia recurrence</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="3">Hernia recurrence during entire postop follow-up<sup>1</sup></th></tr><tr><th align="left"/><th align="left">No</th><th align="left">Yes</th><th align="left"><italic>p</italic>-value<sup>2,3</sup></th></tr><tr><th align="left"/><th align="left"><italic>n</italic> = 81 (84%)</th><th align="left"><italic>n</italic> = 16 (16%)</th><th align="left"/></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">64 (24&#x02013;94)</td><td align="left">62 (33&#x02013;78)</td><td align="left">0.509</td></tr><tr><td align="left" colspan="4">Sex</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Female</td><td align="left">41 (51%)</td><td align="left">9 (56%)</td><td align="left">0.787</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Male</td><td align="left">40 (49%)</td><td align="left">7 (44%)</td><td align="left"/></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="left">32 (19&#x02013;53)</td><td align="left">28 (18&#x02013;50)</td><td align="left">0.121</td></tr><tr><td align="left" colspan="4">Diabetes</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">57 (70%)</td><td align="left">8 (50%)</td><td align="left">0.147</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">24 (30%)</td><td align="left">8 (50%)</td><td align="left"/></tr><tr><td align="left" colspan="4">CAD</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">73 (91%)</td><td align="left">15 (94%)</td><td align="left">1.000</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">7 (9%)</td><td align="left">1 (6%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Previous hernia repair</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">47 (59%)</td><td align="left">6 (40%)</td><td align="left">0.258</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">33 (41%)</td><td align="left">9 (60%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Previous mesh implantation</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">46 (61%)</td><td align="left">6 (46%)</td><td align="left">0.366</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">29 (39%)</td><td align="left">7 (54%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Smoking status</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Never</td><td align="left">38 (47%)</td><td align="left">7 (44%)</td><td align="left">1.000</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Current or former</td><td align="left">43 (53%)</td><td align="left">9 (56%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Recent smoking status</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Never smoked</td><td align="left">64 (79%)</td><td align="left">13 (81%)</td><td align="left">1.000</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Current smoker or quit during the past year</td><td align="left">17 (21%)</td><td align="left">3 (19%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Etiology of hernia</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Incisional</td><td align="left">81 (100%)</td><td align="left">16 (100%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Location of hernia</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;ventral</td><td align="left">79 (98%)</td><td align="left">16 (100%)</td><td align="left">1.000</td></tr><tr><td align="left">f lank</td><td align="left">2 (2%)</td><td align="left">0 (0%)</td><td align="left"/></tr><tr><td align="left">Hernia Volume (cm<sup>3</sup>)</td><td align="left"><bold>2316 (140&#x02013;24314)</bold></td><td align="left"><bold>4221 (1398&#x02013;24232)</bold></td><td align="left"><bold>0.077</bold></td></tr><tr><td align="left">Abdominal Cavity Volume (cm<sup>3</sup>)</td><td align="left">46918 (18982&#x02013;113636)</td><td align="left">50580 (19698&#x02013;112922)</td><td align="left">0.697</td></tr><tr><td align="left">Hernia-to-abdominal Cavity Ratio (%)</td><td align="left">5 (0&#x02013;48)</td><td align="left">7 (3&#x02013;99)</td><td align="left">0.108</td></tr><tr><td align="left" colspan="4">Pre-operative Botox injection</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left"><bold>47 (58%)</bold></td><td align="left"><bold>13 (81%)</bold></td><td align="left"><bold>0.097</bold></td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left"><bold>34 (42%)</bold></td><td align="left"><bold>3 (19%)</bold></td><td align="left"/></tr><tr><td align="left" colspan="4">Complication associated with Botox injection</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">35 (100%)</td><td align="left">3 (100%)</td><td align="left"/></tr><tr><td align="left">Botox-to-surgery time (days)</td><td align="left">30 (8&#x02013;58)</td><td align="left">31 (21&#x02013;38)</td><td align="left">0.933</td></tr><tr><td align="left" colspan="4">Retrorectus surgical technique</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">16 (20%)</td><td align="left">6 (38%)</td><td align="left">0.187</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">65 (80%)</td><td align="left">10 (62%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Primary fascial closure</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">6 (7%)</td><td align="left">1 (6%)</td><td align="left">1.000</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">75 (93%)</td><td align="left">15 (94%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Delayed closure</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">75 (93%)</td><td align="left">14 (88%)</td><td align="left">0.615</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">6 (7%)</td><td align="left">2 (12%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Surgical component separation</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">55 (68%)</td><td align="left">11 (69%)</td><td align="left">1.000</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">26 (32%)</td><td align="left">5 (31%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Application of mesh</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">7 (9%)</td><td align="left">1 (6%)</td><td align="left">1.000</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">74 (91%)</td><td align="left">15 (94%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Mesh type</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;None</td><td align="left"><bold>7 (9%)</bold></td><td align="left"><bold>1 (6%)</bold></td><td align="left"><bold>0.020</bold></td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Polypropylene (Prolene)</td><td align="left"><bold>41 (51%)</bold></td><td align="left"><bold>4 (25%)</bold></td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Synthetic Biodegradable (Vicryl, Phasix)</td><td align="left"><bold>8 (10%)</bold></td><td align="left"><bold>4 (25%)</bold></td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Composite Mesh (Bard Ventralex)</td><td align="left"><bold>19 (23%)</bold></td><td align="left"><bold>2 (12%)</bold></td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Biologic (Strattice)</td><td align="left"><bold>6 (7%)</bold></td><td align="left"><bold>5 (31%)</bold></td><td align="left"/></tr><tr><td align="left" colspan="4">Additional intraoperative procedures other than hernia repair</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">62 (77%)</td><td align="left">12 (75%)</td><td align="left">1.000</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">19 (23%)</td><td align="left">4 (25%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Need for blood transfusion during surgery</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">79 (99%)</td><td align="left">15 (94%)</td><td align="left">0.307</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">1 (1%)</td><td align="left">1 (6%)</td><td align="left"/></tr><tr><td align="left">Estimated Blood Loss (ml)</td><td align="left">100 (10&#x02013;1000)</td><td align="left">75 (15&#x02013;1000)</td><td align="left">0.807</td></tr><tr><td align="left">Hospital stay (days)</td><td align="left"><bold>3 (0&#x02013;20)</bold></td><td align="left"><bold>7 (2&#x02013;14)</bold></td><td align="left"><bold>0.002</bold></td></tr><tr><td align="left" colspan="4">Discharge destination</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Home</td><td align="left"><bold>68 (84%)</bold></td><td align="left"><bold>10 (62%)</bold></td><td align="left"><bold>0.088</bold></td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Home w/Assistance</td><td align="left"><bold>8 (10%)</bold></td><td align="left"><bold>5 (31%)</bold></td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Subacute Rehab</td><td align="left"><bold>3 (4%)</bold></td><td align="left"><bold>1 (6%)</bold></td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Inpatient rehab</td><td align="left"><bold>2 (2%)</bold></td><td align="left"><bold>0 (0%)</bold></td><td align="left"/></tr><tr><td align="left" colspan="4">Any complications</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left"><bold>64 (81%)</bold></td><td align="left"><bold>1 (6%)</bold></td><td align="left"><bold>&#x02009;&#x0003c; 0.001</bold></td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left"><bold>15 (19%)</bold></td><td align="left"><bold>15 (94%)</bold></td><td align="left"/></tr><tr><td align="left" colspan="4">Post-operative pain control issues</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left"><bold>80 (99%)</bold></td><td align="left"><bold>13 (81%)</bold></td><td align="left"><bold>0.014</bold></td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left"><bold>1 (1%)</bold></td><td align="left"><bold>3 (19%)</bold></td><td align="left"/></tr><tr><td align="left" colspan="4">Reoperation for hernia repair during hospitalization</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">81 (100%)</td><td align="left">16 (100%)</td><td align="left">na</td></tr><tr><td align="left" colspan="4">30-day hernia reoperation</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;No</td><td align="left">81 (100%)</td><td align="left">16 (100%)</td><td align="left">na</td></tr><tr><td align="left" colspan="4">Alive at last follow-up?</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left">81 (100%)</td><td align="left">16 (100%)</td><td align="left">na</td></tr><tr><td align="left">Follow-up duration (months)</td><td align="left">43 (2&#x02013;81)</td><td align="left">48 (4&#x02013;79)</td><td align="left">0.228</td></tr></tbody></table><table-wrap-foot><p>1. Data summarized as frequency (%) for categorical variables and median (min &#x02013; max) for numerical values</p><p>2. Percentages are compared using the Fisher's exact test, and the median values are compared with the Mann&#x02013;Whitney U test</p><p>3. Statistically significant differences are shown in bold. Statistical significance level is set at 0.10</p></table-wrap-foot></table-wrap></p><p id="Par20">In multivariate logistic regression analysis chemical component separation with Botox was associated with significantly decreased risk of hernia recurrence (OR [95% confidence interval]: 0.06 [0.01&#x02013;0.67], <italic>p</italic>&#x02009;= 0.021) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Factors associated with hernia recurrence in a multivariate logistic regression model. Variables selection has been conducted using the forward stepwise method</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="2">Forward stepwise selection<sup>1</sup></th><th align="left" colspan="2">Final logistic model<sup>2</sup></th></tr><tr><th align="left"/><th align="left">OR (95% CI)</th><th align="left"><italic>p</italic> value</th><th align="left">OR (95% CI)</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Chemical component separation with Botox</td><td align="left"><bold>0.08 (0.01&#x02013;0.59)</bold></td><td align="left"><bold>0.013</bold></td><td align="left"><bold>0.06 (0.01&#x02013;0.67)</bold></td><td char="." align="char"><bold>0.021</bold></td></tr><tr><td align="left">Hernia volume (cm<sup>3</sup>)<sup>3</sup></td><td align="left"><bold>2.94 (1.00&#x02013;8.62)</bold></td><td align="left"><bold>0.050</bold></td><td align="left"><bold>6.70 (0.92&#x02013;48.87)</bold></td><td char="." align="char"><bold>0.061</bold></td></tr><tr><td align="left">Mesh type (composite versus biologic)</td><td align="left"><bold>0.12 (0.01&#x02013;1.07)</bold></td><td align="left"><bold>0.057</bold></td><td align="left">0.09 (0.00&#x02013;2.03)</td><td char="." align="char">0.132</td></tr><tr><td align="left">Any postoperative surgical complications</td><td align="left"><bold>248.44 (13.45&#x02013;4588.14)</bold></td><td align="left"><bold>&#x02009;&#x0003c; 0.001</bold></td><td align="left"><bold>32.89 (0.96&#x02013;1125.00)</bold></td><td char="." align="char"><bold>0.053</bold></td></tr></tbody></table><table-wrap-foot><p>1. Included variables were chemical component separation with Botox, body mass index, postoperative length of hospital stay, hernia volume, hernia-to-abdominal cavity volume ratio, type of implanted mesh, postoperative discharge destination, any postoperative surgical complications, postoperative pain control issues and postoperative follow-up duration</p><p>2. Multivariate logistic regression including the natural logarithm of follow-up duration as the offset variable and adjusted for a significant interaction detected between chemical component separation and mesh type</p><p>3. Standardized value is included in the analysis</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Propensity score-weighted analysis</title><p id="Par21">After propensity score weighting, chemical component separation with Botox injection demonstrated approximately 71% &#x000b1;&#x02009;21% reduced risk of hernia recurrence relative to the non-Botox&#x000a0;group (adjusted base recurrence risk in non-Botox group &#x000b1;&#x02009;standard error: 18% &#x000b1;&#x02009;5%, absolute risk reduction in the Botox group: &#x02212;13% &#x000b1;&#x02009;6%; <italic>p</italic>&#x02009;= 0.045) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par22">Using a propensity score-weighted analysis, this study suggests that chemical component separation with bilateral CT-guided administration of Botox into the muscle layers involved in the ventral hernia may decrease postoperative hernia recurrence rates.</p><p id="Par23">The effectiveness of preoperative Botox injection in reducing hernia defect size and increasing primary closure rates has been demonstrated in a few systematic review and meta-analysis studies [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. The preoperative measurements of the hernia defect have been shown to correlate with the patient&#x02019;s risk of recurrence after surgical repair [<xref ref-type="bibr" rid="CR21">21</xref>]. Studies with variable follow-up durations (1&#x02013;49 months) have reported 0&#x02013;11.4% recurrence rates with preoperative chemical component separation (CCS) with Botox injections [<xref ref-type="bibr" rid="CR17">17</xref>]. This is comparable to the recurrence rate of 8% demonstrated in our study.</p><p id="Par24">Only a small number of comparative studies have assessed effectiveness of preoperative Botox injection on operative success indices of hernia repair in comparison to adjunctive surgical techniques. In a prospective study comparing 40 patients with Botox injection and subsequent open Rives repair with another 40 patients with open component separation, Botox injection was associated with lower rates of surgical site complications. In the same study, 2 recurrences occurred during a median of 19.6 months, none of which was in the Botox group [<xref ref-type="bibr" rid="CR22">22</xref>]. Three propensity score-matched retrospective studies demonstrated comparable recurrence rates between Botox and non-Botox groups [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. In one retrospective cohort of 426 patients, Botox injection was associated with comparable rates of fascial closure when compared to non-Botox group despite significantly larger fascial defect sizes in the Botox group. On the other hand, higher rates of surgical site infection/occurrences were observed in the Botox group [<xref ref-type="bibr" rid="CR25">25</xref>]. CCS with Botox injection was associated with lower rates of surgical site occurrences in multivariate analysis in a propensity score-matched study [<xref ref-type="bibr" rid="CR24">24</xref>]. No significant differences in overall complication rates were observed in our study.</p><p id="Par25">CCS exerts its effect through an anticholinergic mechanism, achieving peak flaccid paralysis as soon as 2&#x000a0;weeks and lasting up to 6&#x000a0;weeks [<xref ref-type="bibr" rid="CR10">10</xref>]. This adjunct results in a smaller preoperative hernia defect which minimizes the intraoperative tension required at the repair site and avoids the'cheese-wiring'effect caused by excessive tension that can lead to dehiscence [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. In a prospective study, maximum hernia defect size reduction was achieved by 3&#x000a0;weeks after Botox injection and no recurrence was observed during 9&#x000a0;months after repair [<xref ref-type="bibr" rid="CR27">27</xref>]. This effect has been shown to last 2&#x02013;3 months and gradually fade away during the subsequent 6&#x02013;9 months [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par26">A consensus proposal has recently been made by the Spanish Association of Surgeons regarding use of Botox injection prior to abdominal wall surgery and proposing a standard informed consent form for the procedure [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par27">The possible effect of surgical technique on rates of recurrence is an important consideration. One Randomized Controlled study of 56 patients comparing transversus abdominis muscle release versus mesh-only repair demonstrated no statistically significant difference in recurrence rates [<xref ref-type="bibr" rid="CR30">30</xref>]. However, in one retrospective study using the Abdominal Core Health Quality Collaborative registry, surgical component separation was associated with lower overall recurrence rates [<xref ref-type="bibr" rid="CR31">31</xref>]. It is confirmed that achieving primary closure significantly reduces recurrence rates, but it remains unconfirmed whether surgical component separation alone has the same association. Since there was no pre-planned classification of surgical techniques, a higher rate of surgical component separation in the Botox group may be explained by several factors. One possibility is that larger hernias were preferentially assigned to the Botox group which is possibly the explanation for a similar difference seen in a previous study [<xref ref-type="bibr" rid="CR25">25</xref>]. Though our data did not indicate a significant size discrepancy. Another explanation is that the hernias in the Botox group may have had other unmeasured characteristics that influenced surgical decision-making. Additionally, observer bias or the Hawthorne effect [<xref ref-type="bibr" rid="CR32">32</xref>] may have played a role, with surgeons potentially opting for component separation more frequently when aware that the patient had received a Botox injection. In our study, evaluation of association between primary fascial closure and recurrence rates was not possible due to an overall high rate of primary fascial closure. An important consideration in our study is that propensity score weighting was applied to minimize potential confounding effects of surgical component separation and follow-up duration.</p><p id="Par28">There is no significant difference in primary fascial closure rates between two groups in the current study. This might be a signal that the smaller number of hernia recurrences in the CCS group may be independent of primary closure.</p><p id="Par29">This study has a number of strengths. First, potential effect of shorter follow-up duration has been minimized via fixation of time effect in the statistical models via offsetting in the regression models and including it in the propensity score calculation. This difference has been observed in previous studies with potential to underestimate recurrence rates in the Botox group. Additionally, attempts have been made to minimize potential confounding effects of significant technical differences at baseline between two study arms using statistical techniques. To this end, doubly-robust propensity score weighting technique has been chosen to achieve the optimum weighting with the minimum statistical estimation bias.</p><p id="Par30">On the other hand, this study is inherently limited by its retrospective design and single-institution setting, leaving it vulnerable to unobserved selection bias. Also, relatively small sample size leaves the study with low statistical power especially in the initial comparative analyses. Additionally, although we have tried to minimize selection bias, multiple confounding factors such as variability in surgical techniques and perioperative variables could not be addressed due to the retrospective nature of the study.</p><p id="Par31">In conclusion, this study suggests that chemical component separation with OnabotulinumtoxinA (Botox) can be an effective method in reducing recurrence rates in large complex ventral hernias. Further prospective studies can be considered to validate this finding.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="data-availability"><title>Data availability</title><p>De-identified data and analysis code are available from the corresponding author upon request and pending&#x000a0;institutional approval.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Disclosure</title><p id="Par32">AB declares consulting fees from W.L. Gore &#x00026; Associates and educational support from Intuitive Surgical, Inc., GF declares education and travel support from Intuitive Surgical, Inc., JC declares consulting fees from Inari, JM declares consulting fees from Stryker. Other authors declare no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Muysoms</surname><given-names>FE</given-names></name><name><surname>Miserez</surname><given-names>M</given-names></name><name><surname>Berrevoet</surname><given-names>F</given-names></name><etal/></person-group><article-title>Classification of primary and incisional abdominal wall hernias</article-title><source>Hernia</source><year>2009</year><volume>13</volume><fpage>407</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1007/s10029-009-0518-x</pub-id><pub-id pub-id-type="pmid">19495920</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Muysoms FE, Miserez M, Berrevoet F et al (2009) Classification of primary and incisional abdominal wall hernias. Hernia 13:407&#x02013;414<pub-id pub-id-type="pmid">19495920</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Passot</surname><given-names>G</given-names></name><name><surname>Villeneuve</surname><given-names>L</given-names></name><name><surname>Sabbagh</surname><given-names>C</given-names></name><etal/></person-group><article-title>Definition of giant ventral hernias: development of standardization through a practice survey</article-title><source>Int J Surg</source><year>2016</year><volume>28</volume><fpage>136</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.ijsu.2016.01.097</pub-id><pub-id pub-id-type="pmid">26889971</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Passot G, Villeneuve L, Sabbagh C et al (2016) Definition of giant ventral hernias: development of standardization through a practice survey. Int J Surg 28:136&#x02013;140<pub-id pub-id-type="pmid">26889971</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>R</given-names></name><name><surname>Thumma</surname><given-names>J</given-names></name><name><surname>Ehlers</surname><given-names>A</given-names></name><etal/></person-group><article-title>Reoperation for recurrence up to 10 years after hernia repair</article-title><source>JAMA</source><year>2022</year><volume>327</volume><fpage>872</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.0744</pub-id><pub-id pub-id-type="pmid">35230401</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Howard R, Thumma J, Ehlers A et al (2022) Reoperation for recurrence up to 10 years after hernia repair. JAMA 327:872&#x02013;874<pub-id pub-id-type="pmid">35230401</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Parker SG, Mallett S, Quinn L et al (2021) Identifying predictors of ventral hernia recurrence: systematic review and meta-analysis. BJS Open 5. 10.1093/bjsopen/zraa071</mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Knaapen L, Buyne O, Slater N et al (2021) Management of complex ventral hernias: results of an international survey. BJS Open 5. 10.1093/bjsopen/zraa057</mixed-citation></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Deerenberg</surname><given-names>EB</given-names></name><name><surname>Timmermans</surname><given-names>L</given-names></name><name><surname>Hogerzeil</surname><given-names>DP</given-names></name><etal/></person-group><article-title>A systematic review of the surgical treatment of large incisional hernia</article-title><source>Hernia</source><year>2015</year><volume>19</volume><fpage>89</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1007/s10029-014-1321-x</pub-id><pub-id pub-id-type="pmid">25380560</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Deerenberg EB, Timmermans L, Hogerzeil DP et al (2015) A systematic review of the surgical treatment of large incisional hernia. Hernia 19:89&#x02013;101<pub-id pub-id-type="pmid">25380560</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Elstner</surname><given-names>KE</given-names></name><name><surname>Read</surname><given-names>JW</given-names></name><name><surname>Rodriguez-Acevedo</surname><given-names>O</given-names></name><etal/></person-group><article-title>Preoperative chemical component relaxation using Botulinum toxin A: enabling laparoscopic repair of complex ventral hernia</article-title><source>Surg Endosc</source><year>2017</year><volume>31</volume><fpage>761</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1007/s00464-016-5030-7</pub-id><pub-id pub-id-type="pmid">27351658</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Elstner KE, Read JW, Rodriguez-Acevedo O et al (2017) Preoperative chemical component relaxation using Botulinum toxin A: enabling laparoscopic repair of complex ventral hernia. Surg Endosc 31:761&#x02013;768<pub-id pub-id-type="pmid">27351658</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Brin</surname><given-names>MF</given-names></name><name><surname>Burstein</surname><given-names>R</given-names></name></person-group><article-title>Botox (onabotulinumtoxinA) mechanism of action</article-title><source>Medicine (Baltimore)</source><year>2023</year><volume>102</volume><fpage>e32372</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000032372</pub-id><pub-id pub-id-type="pmid">37499078</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Brin MF, Burstein R (2023) Botox (onabotulinumtoxinA) mechanism of action. Medicine (Baltimore) 102:e32372<pub-id pub-id-type="pmid">37499078</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Dressler</surname><given-names>D</given-names></name><name><surname>Adib Saberi</surname><given-names>F</given-names></name></person-group><article-title>Botulinum toxin: mechanisms of action</article-title><source>Eur Neurol</source><year>2005</year><volume>53</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1159/000083259</pub-id><pub-id pub-id-type="pmid">15650306</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Dressler D, Adib Saberi F (2005) Botulinum toxin: mechanisms of action. Eur Neurol 53:3&#x02013;9<pub-id pub-id-type="pmid">15650306</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Elhage</surname><given-names>SA</given-names></name><name><surname>Deerenberg</surname><given-names>EB</given-names></name><name><surname>Shao</surname><given-names>JM</given-names></name><etal/></person-group><article-title>The use of botulinum toxin A in chemical component separation: a review of techniques and outcomes</article-title><source>Plast Aesthet Res</source><year>2020</year><volume>7</volume><fpage>16</fpage></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Elhage SA, Deerenberg EB, Shao JM et al (2020) The use of botulinum toxin A in chemical component separation: a review of techniques and outcomes. Plast Aesthet Res 7:16</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="book"><person-group person-group-type="author"><name><surname>Marturano</surname><given-names>MN</given-names></name><name><surname>Ayuso</surname><given-names>SA</given-names></name><name><surname>Heniford</surname><given-names>BT</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Baig</surname><given-names>SJB</given-names></name><name><surname>DeeprajPriya</surname><given-names>P</given-names></name></person-group><article-title>Chemical Component Separation Technique in Hernia Repair</article-title><source>Newer Concepts and Procedures in Hernia Surgery - An Atlas</source><year>2022</year><publisher-loc>Singapore</publisher-loc><publisher-name>Springer Nature Singapore</publisher-name><fpage>209</fpage><lpage>218</lpage></element-citation><mixed-citation id="mc-CR11" publication-type="book">Marturano MN, Ayuso SA, Heniford BT (2022) Chemical Component Separation Technique in Hernia Repair. In: Baig SJB, DeeprajPriya P (eds) Newer Concepts and Procedures in Hernia Surgery - An Atlas. Springer Nature Singapore, Singapore, pp 209&#x02013;218</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Seretis</surname><given-names>F</given-names></name><name><surname>Chrysikos</surname><given-names>D</given-names></name><name><surname>Samolis</surname><given-names>A</given-names></name><name><surname>Troupis</surname><given-names>T</given-names></name></person-group><article-title>Botulinum toxin in the surgical treatment of complex abdominal hernias: a surgical anatomy approach, current evidence and outcomes</article-title><source>In Vivo</source><year>2021</year><volume>35</volume><fpage>1913</fpage><lpage>1920</lpage><pub-id pub-id-type="doi">10.21873/invivo.12457</pub-id><pub-id pub-id-type="pmid">34182463</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Seretis F, Chrysikos D, Samolis A, Troupis T (2021) Botulinum toxin in the surgical treatment of complex abdominal hernias: a surgical anatomy approach, current evidence and outcomes. In Vivo 35:1913&#x02013;1920<pub-id pub-id-type="pmid">34182463</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Zielinski</surname><given-names>MD</given-names></name><name><surname>Goussous</surname><given-names>N</given-names></name><name><surname>Schiller</surname><given-names>HJ</given-names></name><name><surname>Jenkins</surname><given-names>D</given-names></name></person-group><article-title>Chemical components separation with botulinum toxin A: a novel technique to improve primary fascial closure rates of the open abdomen</article-title><source>Hernia</source><year>2013</year><volume>17</volume><fpage>101</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1007/s10029-012-0995-1</pub-id><pub-id pub-id-type="pmid">23001400</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Zielinski MD, Goussous N, Schiller HJ, Jenkins D (2013) Chemical components separation with botulinum toxin A: a novel technique to improve primary fascial closure rates of the open abdomen. Hernia 17:101&#x02013;107<pub-id pub-id-type="pmid">23001400</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Zendejas</surname><given-names>B</given-names></name><name><surname>Khasawneh</surname><given-names>MA</given-names></name><name><surname>Srvantstyan</surname><given-names>B</given-names></name><etal/></person-group><article-title>Outcomes of chemical component paralysis using botulinum toxin for incisional hernia repairs</article-title><source>World J Surg</source><year>2013</year><volume>37</volume><fpage>2830</fpage><lpage>2837</lpage><pub-id pub-id-type="doi">10.1007/s00268-013-2211-6</pub-id><pub-id pub-id-type="pmid">24081529</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Zendejas B, Khasawneh MA, Srvantstyan B et al (2013) Outcomes of chemical component paralysis using botulinum toxin for incisional hernia repairs. World J Surg 37:2830&#x02013;2837<pub-id pub-id-type="pmid">24081529</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>EY</given-names></name><name><surname>Yoo</surname><given-names>JH</given-names></name><name><surname>Rodrigues</surname><given-names>AJ</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>A computerized tomography scan method for calculating the hernia sac and abdominal cavity volume in complex large incisional hernia with loss of domain</article-title><source>Hernia</source><year>2010</year><volume>14</volume><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/s10029-009-0560-8</pub-id><pub-id pub-id-type="pmid">19756913</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Tanaka EY, Yoo JH, Rodrigues AJ Jr et al (2010) A computerized tomography scan method for calculating the hernia sac and abdominal cavity volume in complex large incisional hernia with loss of domain. Hernia 14:63&#x02013;69<pub-id pub-id-type="pmid">19756913</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Kurz</surname><given-names>CF</given-names></name></person-group><article-title>Augmented inverse probability weighting and the double robustness property</article-title><source>Med Decis Making</source><year>2022</year><volume>42</volume><fpage>156</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1177/0272989X211027181</pub-id><pub-id pub-id-type="pmid">34225519</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Kurz CF (2022) Augmented inverse probability weighting and the double robustness property. Med Decis Making 42:156&#x02013;167<pub-id pub-id-type="pmid">34225519</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Barretto</surname><given-names>VRD</given-names></name><name><surname>de Oliveira</surname><given-names>JGR</given-names></name><name><surname>Brim</surname><given-names>ACS</given-names></name><etal/></person-group><article-title>Botulinum toxin A in complex incisional hernia repair: a systematic review</article-title><source>Hernia</source><year>2024</year><volume>28</volume><fpage>665</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1007/s10029-023-02892-y</pub-id><pub-id pub-id-type="pmid">37801164</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Barretto VRD, de Oliveira JGR, Brim ACS et al (2024) Botulinum toxin A in complex incisional hernia repair: a systematic review. Hernia 28:665&#x02013;676<pub-id pub-id-type="pmid">37801164</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Dias</surname><given-names>ERM</given-names></name><name><surname>Rondini</surname><given-names>GZ</given-names></name><name><surname>Amaral</surname><given-names>PHF</given-names></name><etal/></person-group><article-title>Systematic review and meta-analysis of the pre-operative application of botulinum toxin for ventral hernia repair</article-title><source>Hernia</source><year>2023</year><volume>27</volume><fpage>807</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1007/s10029-023-02816-w</pub-id><pub-id pub-id-type="pmid">37329437</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Dias ERM, Rondini GZ, Amaral PHF et al (2023) Systematic review and meta-analysis of the pre-operative application of botulinum toxin for ventral hernia repair. Hernia 27:807&#x02013;818<pub-id pub-id-type="pmid">37329437</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Timmer</surname><given-names>AS</given-names></name><name><surname>Claessen</surname><given-names>JJM</given-names></name><name><surname>Atema</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>A systematic review and meta-analysis of technical aspects and clinical outcomes of botulinum toxin prior to abdominal wall reconstruction</article-title><source>Hernia</source><year>2021</year><volume>25</volume><fpage>1413</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1007/s10029-021-02499-1</pub-id><pub-id pub-id-type="pmid">34546475</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Timmer AS, Claessen JJM, Atema JJ et al (2021) A systematic review and meta-analysis of technical aspects and clinical outcomes of botulinum toxin prior to abdominal wall reconstruction. Hernia 25:1413&#x02013;1425<pub-id pub-id-type="pmid">34546475</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>van Rooijen</surname><given-names>MMJ</given-names></name><name><surname>Yurtkap</surname><given-names>Y</given-names></name><name><surname>Allaeys</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fascial closure in giant ventral hernias after preoperative botulinum toxin a and progressive pneumoperitoneum: a systematic review and meta-analysis</article-title><source>Surgery</source><year>2021</year><volume>170</volume><fpage>769</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1016/j.surg.2021.03.027</pub-id><pub-id pub-id-type="pmid">33888320</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">van Rooijen MMJ, Yurtkap Y, Allaeys M et al (2021) Fascial closure in giant ventral hernias after preoperative botulinum toxin a and progressive pneumoperitoneum: a systematic review and meta-analysis. Surgery 170:769&#x02013;776<pub-id pub-id-type="pmid">33888320</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Dietz</surname><given-names>UA</given-names></name><name><surname>Winkler</surname><given-names>MS</given-names></name><name><surname>Hartel</surname><given-names>RW</given-names></name><etal/></person-group><article-title>Importance of recurrence rating, morphology, hernial gap size, and risk factors in ventral and incisional hernia classification</article-title><source>Hernia</source><year>2014</year><volume>18</volume><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s10029-012-0999-x</pub-id><pub-id pub-id-type="pmid">23070583</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Dietz UA, Winkler MS, Hartel RW et al (2014) Importance of recurrence rating, morphology, hernial gap size, and risk factors in ventral and incisional hernia classification. Hernia 18:19&#x02013;30<pub-id pub-id-type="pmid">23070583</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Bueno-Lledo</surname><given-names>J</given-names></name><name><surname>Martinez-Hoed</surname><given-names>J</given-names></name><name><surname>Torregrosa-Gallud</surname><given-names>A</given-names></name><etal/></person-group><article-title>Botulinum toxin to avoid component separation in midline large hernias</article-title><source>Surgery</source><year>2020</year><volume>168</volume><fpage>543</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1016/j.surg.2020.04.050</pub-id><pub-id pub-id-type="pmid">32576404</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Bueno-Lledo J, Martinez-Hoed J, Torregrosa-Gallud A et al (2020) Botulinum toxin to avoid component separation in midline large hernias. Surgery 168:543&#x02013;549<pub-id pub-id-type="pmid">32576404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Deerenberg</surname><given-names>EB</given-names></name><name><surname>Shao</surname><given-names>JM</given-names></name><name><surname>Elhage</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Preoperative botulinum toxin A injection in complex abdominal wall reconstruction- a propensity-scored matched study</article-title><source>Am J Surg</source><year>2021</year><volume>222</volume><fpage>638</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1016/j.amjsurg.2021.01.010</pub-id><pub-id pub-id-type="pmid">33478721</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Deerenberg EB, Shao JM, Elhage SA et al (2021) Preoperative botulinum toxin A injection in complex abdominal wall reconstruction- a propensity-scored matched study. Am J Surg 222:638&#x02013;642<pub-id pub-id-type="pmid">33478721</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Marturano</surname><given-names>MN</given-names></name><name><surname>Ayuso</surname><given-names>SA</given-names></name><name><surname>Ku</surname><given-names>D</given-names></name><etal/></person-group><article-title>Preoperative botulinum toxin A (BTA) injection versus component separation techniques (CST) in complex abdominal wall reconstruction (AWR): a propensity-scored matched study</article-title><source>Surgery</source><year>2023</year><volume>173</volume><fpage>756</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1016/j.surg.2022.07.034</pub-id><pub-id pub-id-type="pmid">36229258</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Marturano MN, Ayuso SA, Ku D et al (2023) Preoperative botulinum toxin A (BTA) injection versus component separation techniques (CST) in complex abdominal wall reconstruction (AWR): a propensity-scored matched study. Surgery 173:756&#x02013;764<pub-id pub-id-type="pmid">36229258</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Fair</surname><given-names>L</given-names></name><name><surname>Leeds</surname><given-names>SG</given-names></name><name><surname>Bokhari</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Achieving fascial closure with preoperative botulinum toxin injections in abdominal wall reconstruction: outcomes from a high-volume center</article-title><source>Updates Surg</source><year>2024</year><volume>76</volume><fpage>2421</fpage><lpage>2428</lpage><pub-id pub-id-type="doi">10.1007/s13304-024-01802-w</pub-id><pub-id pub-id-type="pmid">38507174</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Fair L, Leeds SG, Bokhari SH et al (2024) Achieving fascial closure with preoperative botulinum toxin injections in abdominal wall reconstruction: outcomes from a high-volume center. Updates Surg 76:2421&#x02013;2428<pub-id pub-id-type="pmid">38507174</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Khansa</surname><given-names>I</given-names></name><name><surname>Janis</surname><given-names>JE</given-names></name></person-group><article-title>The 4 principles of complex abdominal wall reconstruction</article-title><source>Plast Reconstr Surg Glob Open</source><year>2019</year><volume>7</volume><fpage>e2549</fpage><pub-id pub-id-type="doi">10.1097/GOX.0000000000002549</pub-id><pub-id pub-id-type="pmid">32042542</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Khansa I, Janis JE (2019) The 4 principles of complex abdominal wall reconstruction. Plast Reconstr Surg Glob Open 7:e2549<pub-id pub-id-type="pmid">32042542</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Ibarra-Hurtado</surname><given-names>TR</given-names></name><name><surname>Nuno-Guzman</surname><given-names>CM</given-names></name><name><surname>Echeagaray-Herrera</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Use of botulinum toxin type a before abdominal wall hernia reconstruction</article-title><source>World J Surg</source><year>2009</year><volume>33</volume><fpage>2553</fpage><lpage>2556</lpage><pub-id pub-id-type="doi">10.1007/s00268-009-0203-3</pub-id><pub-id pub-id-type="pmid">19771472</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Ibarra-Hurtado TR, Nuno-Guzman CM, Echeagaray-Herrera JE et al (2009) Use of botulinum toxin type a before abdominal wall hernia reconstruction. World J Surg 33:2553&#x02013;2556<pub-id pub-id-type="pmid">19771472</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Dressler</surname><given-names>D</given-names></name><name><surname>Saberi</surname><given-names>FA</given-names></name><name><surname>Barbosa</surname><given-names>ER</given-names></name></person-group><article-title>Botulinum toxin: mechanisms of action</article-title><source>Arq Neuropsiquiatr</source><year>2005</year><volume>63</volume><fpage>180</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1590/S0004-282X2005000100035</pub-id><pub-id pub-id-type="pmid">15830090</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Dressler D, Saberi FA, Barbosa ER (2005) Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 63:180&#x02013;185<pub-id pub-id-type="pmid">15830090</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Pous-Serrano</surname><given-names>S</given-names></name><name><surname>Bueno-Lledo</surname><given-names>J</given-names></name><name><surname>Garcia-Pastor</surname><given-names>P</given-names></name><etal/></person-group><article-title>Use of botulinum toxin type A in the prehabilitation of abdominal wall musculature for hernia repair: a consensus proposal</article-title><source>Cir Esp (Engl Ed)</source><year>2024</year><volume>102</volume><fpage>391</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1016/j.ciresp.2023.12.004</pub-id><pub-id pub-id-type="pmid">38342140</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Pous-Serrano S, Bueno-Lledo J, Garcia-Pastor P et al (2024) Use of botulinum toxin type A in the prehabilitation of abdominal wall musculature for hernia repair: a consensus proposal. Cir Esp (Engl Ed) 102:391&#x02013;399<pub-id pub-id-type="pmid">38342140</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Rabie</surname><given-names>M</given-names></name><name><surname>Abdelnaby</surname><given-names>M</given-names></name><name><surname>Morshed</surname><given-names>M</given-names></name><name><surname>Shalaby</surname><given-names>M</given-names></name></person-group><article-title>Posterior component separation with transversus abdominis muscle release versus mesh-only repair in the treatment of complex ventral-wall hernia: a randomized controlled trial</article-title><source>BMC Surg</source><year>2022</year><volume>22</volume><fpage>346</fpage><pub-id pub-id-type="doi">10.1186/s12893-022-01794-7</pub-id><pub-id pub-id-type="pmid">36127722</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Rabie M, Abdelnaby M, Morshed M, Shalaby M (2022) Posterior component separation with transversus abdominis muscle release versus mesh-only repair in the treatment of complex ventral-wall hernia: a randomized controlled trial. BMC Surg 22:346<pub-id pub-id-type="pmid">36127722</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Bhardwaj</surname><given-names>P</given-names></name><name><surname>Huayllani</surname><given-names>MT</given-names></name><name><surname>Olson</surname><given-names>MA</given-names></name><name><surname>Janis</surname><given-names>JE</given-names></name></person-group><article-title>Year-over-year ventral hernia recurrence rates and risk factors</article-title><source>JAMA Surg</source><year>2024</year><volume>159</volume><fpage>651</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1001/jamasurg.2024.0233</pub-id><pub-id pub-id-type="pmid">38536183</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Bhardwaj P, Huayllani MT, Olson MA, Janis JE (2024) Year-over-year ventral hernia recurrence rates and risk factors. JAMA Surg 159:651&#x02013;658<pub-id pub-id-type="pmid">38536183</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Demetriou</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>TO</given-names></name><name><surname>Hing</surname><given-names>CB</given-names></name></person-group><article-title>Hawthorne effect on surgical studies</article-title><source>ANZ J Surg</source><year>2019</year><volume>89</volume><fpage>1567</fpage><lpage>1576</lpage><pub-id pub-id-type="doi">10.1111/ans.15475</pub-id><pub-id pub-id-type="pmid">31621178</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Demetriou C, Hu L, Smith TO, Hing CB (2019) Hawthorne effect on surgical studies. ANZ J Surg 89:1567&#x02013;1576<pub-id pub-id-type="pmid">31621178</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>